Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...

Leerink Partners assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research note issued to ...

Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...

Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...

Leerink Partners analyst Faisal Khurshid initiated coverage on aTyr Pharma Inc ATYR with an Outperform rating and announced a ...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, aTyr Pharma (NASDAQ:ATYR) shareholders have done very well over the last year, with the share ...

In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on aTyr Pharma (ATYR – Research Report), with a price target ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ...

aTyr Pharma, Inc. announced it will present three posters at the American Thoracic Society (ATS) 2025 International Conference in San Francisco, showcasing its lead candidate efzofitimod ...